US 11,787,771 B2
Hydrazide containing nuclear transport modulators and uses thereof
Vincent P. Sandanayaka, Northboro, MA (US); Sharon Shacham, Newton, MA (US); Dilara McCauley, Arlington, MA (US); and Sharon Shechter, Andover, MA (US)
Assigned to Karyopharm Therapeutics Inc., Newton, MA (US)
Filed by Karyopharm Therapeutics inc., Newton, MA (US)
Filed on May 14, 2021, as Appl. No. 17/321,029.
Application 17/321,029 is a continuation of application No. 16/696,702, filed on Nov. 26, 2019, granted, now 11,034,660.
Application 16/696,702 is a continuation of application No. 16/203,181, filed on Nov. 28, 2018, granted, now 10,544,108, issued on Jan. 28, 2020.
Application 16/203,181 is a continuation of application No. 15/629,307, filed on Jun. 21, 2017, granted, now 10,173,987, issued on Jan. 8, 2019.
Application 15/629,307 is a continuation of application No. 14/940,310, filed on Nov. 13, 2015, granted, now 9,714,226, issued on Jul. 25, 2017.
Application 14/940,310 is a continuation of application No. 14/735,853, filed on Jun. 10, 2015, granted, now 9,206,158, issued on Dec. 8, 2015.
Application 14/735,853 is a continuation of application No. 14/235,306, granted, now 9,079,865, issued on Jul. 14, 2015, previously published as PCT/US2012/048319, filed on Jul. 26, 2012.
Claims priority of provisional application 61/654,651, filed on Jun. 1, 2012.
Claims priority of provisional application 61/653,588, filed on May 31, 2012.
Claims priority of provisional application 61/610,178, filed on Mar. 13, 2012.
Claims priority of provisional application 61/513,432, filed on Jul. 29, 2011.
Claims priority of provisional application 61/513,428, filed on Jul. 29, 2011.
Prior Publication US 2022/0073478 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 249/08 (2006.01); A61K 31/497 (2006.01); C07D 241/20 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 409/12 (2006.01); A61K 31/4196 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/498 (2006.01); A61K 31/506 (2006.01); A61K 31/55 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01)
CPC C07D 249/08 (2013.01) [A61K 31/4196 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); C07D 241/20 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 409/12 (2013.01)] 12 Claims
 
1. A method for treating a disorder associated with CRM1 activity comprising administering to a subject in need thereof a therapeutically effective amount of a compound represented by the following structural formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.